查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1371910

阿茲海默症藥物的全球市場，預測到 2030 年：按產品、最終用戶和地區進行的全球分析

Alzheimer's Therapeutics Market Forecasts to 2030 - Global Analysis By Product (Cholinesterase Inhibitors, N -Methyl-D-Aspartate Receptor Antagonists and Other Products), End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據Stratistics MRC預測，2023年全球阿茲海默症藥物市場規模將達73億美元，預計2030年將達到145億美元，預測期內年複合成長率為10.1%。

阿茲海默症是一種神經系統疾病，會導致大腦萎縮和腦細胞死亡。它是失智症最常見的原因，導致思考、行動和社交技能持續下降，影響一個人的獨立能力。該疾病的早期症狀包括忘記最近發生的事件或談話。

根據《阿茲海默症協會雜誌》報道，在美國， 65 歲以上的老年人中有 10.7%（即每 9 人中就有 1 人）患有阿茲海默失智症。

對有效治療方法的需求不斷成長

隨著世界人口高齡化，阿茲海默症的患病不斷增加，迫切需要減緩其進展或緩解症狀的治療方法。這種需求正在推動新藥和治療方法開發的研究和投資。製藥公司正在積極探索緩解疾病藥物和精準醫療等創新方法，以解決這項未滿足的醫療需求。此外，對改善阿茲海默症患者生活品質的關注也推動了支持性護理產品和服務的市場，使其成為醫療保健行業中一個利潤豐厚且不斷發展的領域。

阿茲海默症藥物研發成本高昂

開發阿茲海默症的有效治療方法是一個複雜且耗時的過程，通常涉及長期的臨床試驗和嚴格的法規要求。阿茲海默症藥物的研發失敗率極高，投入大量資金卻難保成功。這些急劇上升的研發成本可能會阻礙製藥公司進行阿茲海默症藥物開發，並限制潛在治療方法的數量。此外，此類研發成本可能導致藥品價格急劇上升，對病患和醫療保健系統帶來經濟挑戰，進一步阻礙獲得重要治療方法。

開發精準醫學和基因治療等創新方法

精準醫學根據個體的遺傳和分子特徵量身訂做治療方案，有可能帶來更有效和個體化的治療。另一方面，基因療法旨在透過針對特定的基因突變或異常蛋白質來解決阿茲海默症的根本原因。這些突破性技術有可能改變疾病的進程，並為預防和治療帶來希望。隨著這些領域研究的進展，更精確、更有影響力和潛在治癒性的干涉措施將成為可能，這是對抗阿茲海默症的重要一步。

核准流程漫長而複雜

開拓阿茲海默症新藥市場是一項耗時且配合措施，通常需要十多年的時間。嚴格的法規要求，包括廣泛的臨床試驗和嚴格的安全性評估，顯著增加了核准所需的時間和成本。阿茲海默失智症藥物開發中的高停藥率進一步加劇了這項挑戰。延遲獲得監管核准不僅會阻礙製藥公司，還會阻止患者獲得可能改變生活的治療方法。

COVID-19 的影響

COVID-19大流行對阿茲海默症市場產生了多方面的影響。一方面，旨在開發新的阿茲海默症藥物的臨床試驗和研究工作受到干擾，導致延誤和挫折。此外，為了應對大流行而重新分配醫療保健資源，使阿茲海默症患者可獲得的護理和支持變得緊張。社會隔離措施加劇了這個弱勢族群的認知能力下降和心理健康問題。同時，這場大流行凸顯了阿茲海默症患者對創新遠端監控和遠端醫療解決方案的需求。它也強調了長期照護機構做好準備的重要性。

膽鹼酯酶抑制劑細分市場預計將在預測期內成為最大的細分市場

膽鹼酯酶抑制劑領域預計將出現良好的成長。這些藥物包括多奈哌齊、卡巴拉汀和加蘭他敏等藥物，旨在透過增加大腦中神經傳導物質乙醯膽鹼的水平來緩解認知症狀。這些藥物可以暫時緩解記憶和認知障礙，並提高阿茲海默症患者的生活品質。膽鹼酯酶抑制劑是治療的主要藥物，但它們不是治療藥物。隨著阿茲海默症患病的增加，這些藥物的市場持續成長，同時不斷研究開發針對這種破壞性神經退化性疾病的更有效和更有針對性的治療方法。

預計藥局部門在預測期內年複合成長率最高

預計藥局領域在預測期內將以最快的年複合成長率成長。這些零售商出售多種藥物，包括膽鹼酯酶抑制劑和美金剛，這些藥物通常用於治療阿茲海默症症狀。此外，藥局還提供非處方產品，例如對阿茲海默症患者及其看護者很重要的補充劑和醫療用品。對於尋求治療阿茲海默症資訊和支持的家庭來說，藥局通常是寶貴的資訊來源。隨著阿茲海默症患病的增加，藥局越來越注重提供針對該患者群體的獨特需求的專門服務和產品，而藥局也越來越注重提供針對該患者群體的獨特需求的專門服務和產品。做出了很大的貢獻。

佔比最高的地區

在預測期內，北美阿茲海默症藥物市場預計將繼續佔據大部分市場佔有率，因為它是醫療保健產業中一個充滿活力且快速發展的領域。該市場包括藥品、生技藥品以及用於管理和治療阿茲海默症（神經退化性疾病）的新興療法。隨著人口高齡化的加劇和人們對阿茲海默症的認知不斷增強，市場正在大力投資研發。主要企業正在研究創新方法，包括緩解疾病藥物和精準醫療，以解決阿茲海默症的複雜性。

複合年複合成長率最高的地區：

預計亞太地區在預測期內的年複合成長率最高。由於高齡化和醫療基礎設施的改善，阿茲海默症的患病正在上升。日本、中國和韓國等國家正大力投資阿茲海默症治療方法的研發，導致藥品市場競爭激烈。然而，挑戰依然存在，例如診斷延遲、認知度低以及醫療保健系統的地區差異。法規障礙和文化偏見也會影響患者護理和獲得創新治療方法的機會。儘管如此，由於公共衛生問題日益嚴重，迫切需要有效的治療方法，亞太地區阿茲海默症市場具有巨大的成長潛力。

免費客製化服務

訂閱此報告的客戶可以利用以下免費自訂選項之一：

  • 公司簡介
    • 其他市場公司的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 利害關係人
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究來源
    • 主要研究來源
    • 二次研究來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球阿茲海默症藥物市場：依產品

  • 膽鹼酯酶抑制劑
    • 多奈哌齊
    • 卡巴拉汀
    • 加蘭他敏
  • N-甲基-D-天門冬胺酸 (NMDA) 受體拮抗
  • 組合藥物
  • 其他產品

第6章 全球阿茲海默症藥物市場：依最終用戶分類

  • 醫院藥房
  • 零售藥房
  • 藥局
  • 網路藥房
  • 其他最終用戶

第7章 全球阿茲海默症藥物市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東/非洲

第8章 進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第9章 公司簡介

  • Cipla Ltd.
  • Daiichi Sankyo Company, Limited
  • Dr. Reddy's Laboratories Ltd
  • Amneal Pharmaceuticals Inc.
  • Aurobindo Pharma Ltd
  • AbbVie, Inc.
  • Eisai Co., Ltd.
  • Adamas Pharmaceuticals, Inc.
  • F. Hoffmann La Roche Ltd.
  • H. Lundbeck A/S
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • TauRx Pharmaceuticals Ltd.
  • Lannett Inc.
  • Lupin Ltd
  • Macleods Pharmaceuticals Ltd.
Product Code: SMRC23967

According to Stratistics MRC, the Global Alzheimer's Therapeutics Market is accounted for $7.3 billion in 2023 and is expected to reach $14.5 billion by 2030 growing at a CAGR of 10.1% during the forecast period. Alzheimer's disease is a neurological disorder that causes the brain to shrink (atrophy) and brain cells to die. It is the most common cause of dementia that leads to continuous decline in thinking, behavioral and social skills that affects the ability of a person to function independently. The early signs of the disease include forgetting recent events or conversations.

According to the Journal of the Alzheimer's Association, In the United States, around 1 in 9 people which comprised 10.7% of the people aged 65 and older are having Alzheimer's dementia.

Market Dynamics:

Driver:

Growing demand for effective treatments

As the global population ages, the prevalence of Alzheimer's disease is increasing, creating a pressing need for therapies that can slow down its progression or alleviate its symptoms. This demand has spurred increased research and investment in the development of new drugs and therapies. Pharmaceutical companies are actively seeking innovative approaches, such as disease-modifying drugs and precision medicine, to address this unmet medical need. Additionally, the focus on improving the quality of life for Alzheimer's patients has driven the market for supportive care products and services, making it a lucrative and evolving sector in the healthcare industry.

Restraint:

High cost of research and development for Alzheimer's drugs

Developing effective treatments for Alzheimer's disease is an intricate and time-consuming process, often involving lengthy clinical trials and rigorous regulatory requirements. The failure rate in Alzheimer's drug development is notably high, leading to substantial financial investments without guaranteed success. These elevated R&D costs can discourage pharmaceutical companies from pursuing Alzheimer's drug development, limiting the number of potential treatments. Moreover, these expenses can subsequently result in high medication prices, which may pose affordability challenges for patients and healthcare systems, thus further hindering access to these crucial therapies.

Opportunity:

Development of innovative approaches such as precision medicine and gene therapy

Precision medicine tailors treatments to an individual's genetic and molecular profile, potentially leading to more effective and personalized therapies. Gene therapy, on the other hand, aims to address the root causes of Alzheimer's by targeting specific genetic mutations or aberrant proteins. These groundbreaking techniques hold the potential to modify the course of the disease, offering hope for both prevention and treatment. As research in these areas progresses, they offer the prospect of more precise, impactful, and potentially curative interventions, marking a significant step forward in the fight against Alzheimer's.

Threat:

The lengthy and complex regulatory approval process

Developing and bringing new Alzheimer's drugs to market is a time-consuming and resource-intensive endeavor, often spanning over a decade. The stringent regulatory requirements, including extensive clinical trials and rigorous safety evaluations, significantly extend the time and cost required for approval. The high attrition rate in Alzheimer's drug development further exacerbates this challenge. Delays in obtaining regulatory clearance not only deter pharmaceutical companies but also hinder patient access to potentially life-changing treatments.

COVID-19 Impact:

The COVID-19 pandemic has had a multifaceted impact on the Alzheimer's market. On one hand, it disrupted clinical trials and research efforts aimed at developing new Alzheimer's treatments, causing delays and setbacks. Additionally, the redirection of healthcare resources towards pandemic response strained the care and support available for Alzheimer's patients. Social isolation measures exacerbated cognitive decline and mental health issues among this vulnerable population. On the other hand, the pandemic highlighted the need for innovative remote monitoring and telehealth solutions for Alzheimer's patients. It also underscored the importance of preparedness in long-term care facilities.

The cholinesterase inhibitors segment is expected to be the largest during the forecast period

The cholinesterase inhibitors segment is expected to have lucrative growth. These medications, including drugs like Donepezil, Rivastigmine, and Galantamine, are designed to alleviate cognitive symptoms by enhancing the levels of acetylcholine, a neurotransmitter in the brain. They provide temporary relief from memory and cognitive impairments, improving the quality of life for Alzheimer's patients. Cholinesterase inhibitors have been a mainstay of treatment, though they do not offer a cure. With the increasing prevalence of Alzheimer's, the market for these drugs continues to grow, alongside ongoing research to develop more effective and targeted treatments for this devastating neurodegenerative disease.

The drug stores segment is expected to have the highest CAGR during the forecast period

The drug stores segment is anticipated to witness the fastest CAGR growth during the forecast period. These retail outlets offer a wide range of pharmaceuticals, including cholinesterase inhibitors and memantine, which are commonly prescribed to manage Alzheimer's symptoms. Additionally, drug stores provide over-the-counter products such as supplements and medical supplies, crucial for Alzheimer's patients and their caregivers. They often serve as a valuable resource for families seeking information and support for managing the disease. With the rising prevalence of Alzheimer's, drug stores are increasingly focused on providing specialized services and products tailored to the unique needs of this patient population, thus contributing significantly to Alzheimer's care and treatment.

Region with largest share:

During the forecast period, it is expected that the North America Alzheimer's Therapeutics market will continue to hold a majority of the market share due to its dynamic and rapidly evolving sector within the healthcare industry. It encompasses a range of pharmaceuticals, biologics, and emerging therapies aimed at managing and treating Alzheimer's disease, a prevalent neurodegenerative condition. With a growing aging population and increasing awareness of Alzheimer's, the market is witnessing significant investments in research and development. Key players are working on innovative approaches, including disease-modifying drugs and precision medicine, to address the complex nature of Alzheimer's.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period. With a rapidly aging population and improving healthcare infrastructure, the prevalence of Alzheimer's is on the rise. Countries like Japan, China, and South Korea are investing heavily in research and development for Alzheimer's treatments, leading to a competitive pharmaceutical market. However, challenges such as underdiagnosis, limited awareness, and varying healthcare systems across the region persist. Regulatory hurdles and cultural stigmas also impact patient care and access to innovative therapies. Nonetheless, the Asia Pacific Alzheimer's market holds significant growth potential, driven by a pressing need for effective treatments in the face of this escalating public health concern.

Key players in the market:

Some of the key players in Alzheimer's Therapeutics Market include: Cipla Ltd., Daiichi Sankyo Company, Limited, Dr. Reddy's Laboratories Ltd, Amneal Pharmaceuticals Inc., Aurobindo Pharma Ltd, AbbVie, Inc., Eisai Co., Ltd., Adamas Pharmaceuticals, Inc., F. Hoffmann La Roche Ltd., H. Lundbeck A/S, Johnson & Johnson Services, Inc., Novartis AG, Sun Pharmaceutical Industries Ltd., TauRx Pharmaceuticals Ltd., Lannett Inc., Lupin Ltd and Macleods Pharmaceuticals Ltd.

Key Developments:

In March 2023, Biogen Inc. and Eisai Co., expanded their collaboration to find therapeutics treatments of the disease.

In December 2022, Kashiv Specialty Pharmaceuticals is acquired by Amneal. Amneal obtained access to the pipeline of complex generics and branded 505(b)2 medicines through this arrangement.

In May 2022, Amneal completed the acquisition of Kashiv Specialty Pharmaceuticals. Through this acquisition, Amneal gained the pipeline of 505(b)2 branded products and complex generics.

Products Covered:

  • Cholinesterase Inhibitors
  • N -Methyl-D-Aspartate (NMDA) Receptor Antagonists
  • Combination Drug
  • Other Products

End Users Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Alzheimer's Therapeutics Market, By Product

  • 5.1 Introduction
  • 5.2 Cholinesterase Inhibitors
    • 5.2.1 Donepezil
    • 5.2.2 Rivastigmine
    • 5.2.3 Galantamine
  • 5.3 N -Methyl-D-Aspartate (NMDA) Receptor Antagonists
  • 5.4 Combination Drug
  • 5.5 Other Products

6 Global Alzheimer's Therapeutics Market, By End User

  • 6.1 Introduction
  • 6.2 Hospital Pharmacies
  • 6.3 Retail Pharmacies
  • 6.4 Drug Stores
  • 6.5 Online Pharmacies
  • 6.6 Other End Users

7 Global Alzheimer's Therapeutics Market, By Geography

  • 7.1 Introduction
  • 7.2 North America
    • 7.2.1 US
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 UK
    • 7.3.3 Italy
    • 7.3.4 France
    • 7.3.5 Spain
    • 7.3.6 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 Japan
    • 7.4.2 China
    • 7.4.3 India
    • 7.4.4 Australia
    • 7.4.5 New Zealand
    • 7.4.6 South Korea
    • 7.4.7 Rest of Asia Pacific
  • 7.5 South America
    • 7.5.1 Argentina
    • 7.5.2 Brazil
    • 7.5.3 Chile
    • 7.5.4 Rest of South America
  • 7.6 Middle East & Africa
    • 7.6.1 Saudi Arabia
    • 7.6.2 UAE
    • 7.6.3 Qatar
    • 7.6.4 South Africa
    • 7.6.5 Rest of Middle East & Africa

8 Key Developments

  • 8.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 8.2 Acquisitions & Mergers
  • 8.3 New Product Launch
  • 8.4 Expansions
  • 8.5 Other Key Strategies

9 Company Profiling

  • 9.1 Cipla Ltd.
  • 9.2 Daiichi Sankyo Company, Limited
  • 9.3 Dr. Reddy's Laboratories Ltd
  • 9.4 Amneal Pharmaceuticals Inc.
  • 9.5 Aurobindo Pharma Ltd
  • 9.6 AbbVie, Inc.
  • 9.7 Eisai Co., Ltd.
  • 9.8 Adamas Pharmaceuticals, Inc.
  • 9.9 F. Hoffmann La Roche Ltd.
  • 9.10 H. Lundbeck A/S
  • 9.11 Johnson & Johnson Services, Inc.
  • 9.12 Novartis AG
  • 9.13 Sun Pharmaceutical Industries Ltd.
  • 9.14 TauRx Pharmaceuticals Ltd.
  • 9.15 Lannett Inc.
  • 9.16 Lupin Ltd
  • 9.17 Macleods Pharmaceuticals Ltd.

List of Tables

  • Table 1 Global Alzheimer's Therapeutics Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Alzheimer's Therapeutics Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Alzheimer's Therapeutics Market Outlook, By Cholinesterase Inhibitors (2021-2030) ($MN)
  • Table 4 Global Alzheimer's Therapeutics Market Outlook, By Donepezil (2021-2030) ($MN)
  • Table 5 Global Alzheimer's Therapeutics Market Outlook, By Rivastigmine (2021-2030) ($MN)
  • Table 6 Global Alzheimer's Therapeutics Market Outlook, By Galantamine (2021-2030) ($MN)
  • Table 7 Global Alzheimer's Therapeutics Market Outlook, By N -Methyl-D-Aspartate (NMDA) Receptor Antagonists (2021-2030) ($MN)
  • Table 8 Global Alzheimer's Therapeutics Market Outlook, By Combination Drug (2021-2030) ($MN)
  • Table 9 Global Alzheimer's Therapeutics Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 10 Global Alzheimer's Therapeutics Market Outlook, By End User (2021-2030) ($MN)
  • Table 11 Global Alzheimer's Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 12 Global Alzheimer's Therapeutics Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 13 Global Alzheimer's Therapeutics Market Outlook, By Drug Stores (2021-2030) ($MN)
  • Table 14 Global Alzheimer's Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 15 Global Alzheimer's Therapeutics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 16 North America Alzheimer's Therapeutics Market Outlook, By Country (2021-2030) ($MN)
  • Table 17 North America Alzheimer's Therapeutics Market Outlook, By Product (2021-2030) ($MN)
  • Table 18 North America Alzheimer's Therapeutics Market Outlook, By Cholinesterase Inhibitors (2021-2030) ($MN)
  • Table 19 North America Alzheimer's Therapeutics Market Outlook, By Donepezil (2021-2030) ($MN)
  • Table 20 North America Alzheimer's Therapeutics Market Outlook, By Rivastigmine (2021-2030) ($MN)
  • Table 21 North America Alzheimer's Therapeutics Market Outlook, By Galantamine (2021-2030) ($MN)
  • Table 22 North America Alzheimer's Therapeutics Market Outlook, By N -Methyl-D-Aspartate (NMDA) Receptor Antagonists (2021-2030) ($MN)
  • Table 23 North America Alzheimer's Therapeutics Market Outlook, By Combination Drug (2021-2030) ($MN)
  • Table 24 North America Alzheimer's Therapeutics Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 25 North America Alzheimer's Therapeutics Market Outlook, By End User (2021-2030) ($MN)
  • Table 26 North America Alzheimer's Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 27 North America Alzheimer's Therapeutics Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 28 North America Alzheimer's Therapeutics Market Outlook, By Drug Stores (2021-2030) ($MN)
  • Table 29 North America Alzheimer's Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 30 North America Alzheimer's Therapeutics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 31 Europe Alzheimer's Therapeutics Market Outlook, By Country (2021-2030) ($MN)
  • Table 32 Europe Alzheimer's Therapeutics Market Outlook, By Product (2021-2030) ($MN)
  • Table 33 Europe Alzheimer's Therapeutics Market Outlook, By Cholinesterase Inhibitors (2021-2030) ($MN)
  • Table 34 Europe Alzheimer's Therapeutics Market Outlook, By Donepezil (2021-2030) ($MN)
  • Table 35 Europe Alzheimer's Therapeutics Market Outlook, By Rivastigmine (2021-2030) ($MN)
  • Table 36 Europe Alzheimer's Therapeutics Market Outlook, By Galantamine (2021-2030) ($MN)
  • Table 37 Europe Alzheimer's Therapeutics Market Outlook, By N -Methyl-D-Aspartate (NMDA) Receptor Antagonists (2021-2030) ($MN)
  • Table 38 Europe Alzheimer's Therapeutics Market Outlook, By Combination Drug (2021-2030) ($MN)
  • Table 39 Europe Alzheimer's Therapeutics Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 40 Europe Alzheimer's Therapeutics Market Outlook, By End User (2021-2030) ($MN)
  • Table 41 Europe Alzheimer's Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 42 Europe Alzheimer's Therapeutics Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 43 Europe Alzheimer's Therapeutics Market Outlook, By Drug Stores (2021-2030) ($MN)
  • Table 44 Europe Alzheimer's Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 45 Europe Alzheimer's Therapeutics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 46 Asia Pacific Alzheimer's Therapeutics Market Outlook, By Country (2021-2030) ($MN)
  • Table 47 Asia Pacific Alzheimer's Therapeutics Market Outlook, By Product (2021-2030) ($MN)
  • Table 48 Asia Pacific Alzheimer's Therapeutics Market Outlook, By Cholinesterase Inhibitors (2021-2030) ($MN)
  • Table 49 Asia Pacific Alzheimer's Therapeutics Market Outlook, By Donepezil (2021-2030) ($MN)
  • Table 50 Asia Pacific Alzheimer's Therapeutics Market Outlook, By Rivastigmine (2021-2030) ($MN)
  • Table 51 Asia Pacific Alzheimer's Therapeutics Market Outlook, By Galantamine (2021-2030) ($MN)
  • Table 52 Asia Pacific Alzheimer's Therapeutics Market Outlook, By N -Methyl-D-Aspartate (NMDA) Receptor Antagonists (2021-2030) ($MN)
  • Table 53 Asia Pacific Alzheimer's Therapeutics Market Outlook, By Combination Drug (2021-2030) ($MN)
  • Table 54 Asia Pacific Alzheimer's Therapeutics Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 55 Asia Pacific Alzheimer's Therapeutics Market Outlook, By End User (2021-2030) ($MN)
  • Table 56 Asia Pacific Alzheimer's Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 57 Asia Pacific Alzheimer's Therapeutics Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 58 Asia Pacific Alzheimer's Therapeutics Market Outlook, By Drug Stores (2021-2030) ($MN)
  • Table 59 Asia Pacific Alzheimer's Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 60 Asia Pacific Alzheimer's Therapeutics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 61 South America Alzheimer's Therapeutics Market Outlook, By Country (2021-2030) ($MN)
  • Table 62 South America Alzheimer's Therapeutics Market Outlook, By Product (2021-2030) ($MN)
  • Table 63 South America Alzheimer's Therapeutics Market Outlook, By Cholinesterase Inhibitors (2021-2030) ($MN)
  • Table 64 South America Alzheimer's Therapeutics Market Outlook, By Donepezil (2021-2030) ($MN)
  • Table 65 South America Alzheimer's Therapeutics Market Outlook, By Rivastigmine (2021-2030) ($MN)
  • Table 66 South America Alzheimer's Therapeutics Market Outlook, By Galantamine (2021-2030) ($MN)
  • Table 67 South America Alzheimer's Therapeutics Market Outlook, By N -Methyl-D-Aspartate (NMDA) Receptor Antagonists (2021-2030) ($MN)
  • Table 68 South America Alzheimer's Therapeutics Market Outlook, By Combination Drug (2021-2030) ($MN)
  • Table 69 South America Alzheimer's Therapeutics Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 70 South America Alzheimer's Therapeutics Market Outlook, By End User (2021-2030) ($MN)
  • Table 71 South America Alzheimer's Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 72 South America Alzheimer's Therapeutics Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 73 South America Alzheimer's Therapeutics Market Outlook, By Drug Stores (2021-2030) ($MN)
  • Table 74 South America Alzheimer's Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 75 South America Alzheimer's Therapeutics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 76 Middle East & Africa Alzheimer's Therapeutics Market Outlook, By Country (2021-2030) ($MN)
  • Table 77 Middle East & Africa Alzheimer's Therapeutics Market Outlook, By Product (2021-2030) ($MN)
  • Table 78 Middle East & Africa Alzheimer's Therapeutics Market Outlook, By Cholinesterase Inhibitors (2021-2030) ($MN)
  • Table 79 Middle East & Africa Alzheimer's Therapeutics Market Outlook, By Donepezil (2021-2030) ($MN)
  • Table 80 Middle East & Africa Alzheimer's Therapeutics Market Outlook, By Rivastigmine (2021-2030) ($MN)
  • Table 81 Middle East & Africa Alzheimer's Therapeutics Market Outlook, By Galantamine (2021-2030) ($MN)
  • Table 82 Middle East & Africa Alzheimer's Therapeutics Market Outlook, By N -Methyl-D-Aspartate (NMDA) Receptor Antagonists (2021-2030) ($MN)
  • Table 83 Middle East & Africa Alzheimer's Therapeutics Market Outlook, By Combination Drug (2021-2030) ($MN)
  • Table 84 Middle East & Africa Alzheimer's Therapeutics Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 85 Middle East & Africa Alzheimer's Therapeutics Market Outlook, By End User (2021-2030) ($MN)
  • Table 86 Middle East & Africa Alzheimer's Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 87 Middle East & Africa Alzheimer's Therapeutics Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 88 Middle East & Africa Alzheimer's Therapeutics Market Outlook, By Drug Stores (2021-2030) ($MN)
  • Table 89 Middle East & Africa Alzheimer's Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 90 Middle East & Africa Alzheimer's Therapeutics Market Outlook, By Other End Users (2021-2030) ($MN)